8-K: Adverum Accelerates ARTEMIS Trial Milestones for Ixo-vec

Adverum Biotechnologies announced accelerated timelines for its pivotal Phase 3 ARTEMIS trial of Ixo-vec for wet AMD, with screening completed ahead of schedule and full enrollment and topline data expected sooner.

Summary

• Completion of screening in the pivotal Phase 3 ARTEMIS trial evaluating Ixo-vec in wet age-related macular degeneration (wet AMD) was announced.
• Screening was completed by September 30, 2025, seven months after initiation, which is ahead of expectations.
• Full enrollment of at least 284 treatment-naive and treatment-experienced patients in the ARTEMIS trial is now anticipated in Q4 2025, accelerated from the previously expected Q1 2026.
• Topline data from the ARTEMIS trial is now expected to be announced in Q1 2027, an acceleration from prior guidance.
• ARTEMIS is the first of two Phase 3 registrational trials for Ixo-vec in wet AMD, comparing a single administration of Ixo-vec (6E10 vg/eye) to aflibercept (2mg) every 8 weeks.
• Ixo-vec (ixoberogene soroparvovec, formerly ADVM-022) is a clinical-stage gene therapy product candidate designed as a one-time intravitreal (IVT) injection.
• It utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence.
• Ixo-vec has received FDA Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations, EMA PRIME designation, and the Innovation Passport from the UK MHRA for wet AMD.

Sentiment

Score: 9

Explanation: The acceleration of key milestones for the pivotal Phase 3 ARTEMIS trial, including earlier completion of screening, full enrollment, and topline data readout, indicates strong progress and positive momentum for Adverum's lead gene therapy candidate, Ixo-vec. This significantly reduces development timelines and potentially brings the therapy closer to market, which is a substantial positive for a clinical-stage biotechnology company.

Positives

• Screening for the pivotal Phase 3 ARTEMIS trial was completed ahead of expectations, by September 30, 2025.
• Full enrollment for the ARTEMIS trial is now anticipated in Q4 2025, accelerating from the previous expectation of Q1 2026.
• The topline data readout from the ARTEMIS trial is accelerated to Q1 2027.
• Ixo-vec has received multiple expedited regulatory designations, including FDA Fast Track, RMAT, EMA PRIME, and UK MHRA Innovation Passport, highlighting its potential and unmet medical need.
• Ixo-vec is designed as a one-time IVT injection, offering a potential 'One And Done' treatment to reduce the burden of frequent anti-VEGF injections and improve patient compliance for wet AMD.

Risks

• Risks inherent to Adverum's novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials.
• Regulatory uncertainties that could impact the approval process or timelines.
• Enrollment uncertainties, where actual patient enrollment might differ from expectations.
• The results of early clinical trials are not always predictive of future clinical trials and results.
• Potential for future complications or side effects in connection with the use of Ixo-vec.
• Adverum's ability to continue as a going concern and improve its financial position.
• Risks associated with market conditions that could affect the company's operations or stock value.

Future Outlook

Adverum Biotechnologies anticipates completing screening for its pivotal Phase 3 ARTEMIS trial by September 30, 2025, with full enrollment expected in Q4 2025 and topline data readout in Q1 2027. These timelines represent an acceleration compared to previous expectations, indicating strong progress in the development of Ixo-vec for wet AMD and potentially bringing the therapy closer to market.

Management Comments

• The company has notified sites that it plans to complete screening in ARTEMIS by September 30, seven months after initiation, because it now expects full enrollment in Q4 2025 and data readout in Q1 2027.

Industry Context

The development of Ixo-vec by Adverum Biotechnologies is positioned within the growing field of gene therapy for ocular diseases, specifically targeting wet AMD. Current treatments often require frequent injections, creating a significant patient burden. Ixo-vec's 'One And Done' approach, if successful, could represent a significant advancement, potentially disrupting the market dominated by anti-VEGF therapies by offering a more convenient and durable solution. Its multiple expedited regulatory designations highlight the recognized unmet need for new treatment options in this space.

Comparison to Industry Standards

• Ixo-vec is being evaluated against aflibercept (Eylea), a current standard of care for wet AMD, which typically requires injections every 8 weeks.
• The 'One And Done' approach of Ixo-vec aims to significantly reduce the treatment burden compared to existing anti-VEGF therapies from companies like Regeneron (Eylea) and Novartis/Roche (Lucentis, Vabysmo).
• While other gene therapies for ocular diseases exist (e.g., Luxturna for RPE65-mediated inherited retinal dystrophy), Ixo-vec's intravitreal administration method for wet AMD differentiates it from sub-retinal approaches, potentially making it more accessible and less invasive.

Stakeholder Impact

• Shareholders: Positive impact due to accelerated clinical development, potentially de-risking the asset and bringing it closer to commercialization, which could lead to increased shareholder value.
• Patients with wet AMD: Potential for a novel, less burdensome 'One And Done' treatment option if Ixo-vec proves safe and effective, significantly improving their quality of life by reducing the need for frequent injections.
• Healthcare providers: Potential for a new treatment paradigm that simplifies administration compared to frequent injections, streamlining clinical workflows and patient management.

Next Steps

• Achieve full enrollment of the ARTEMIS trial in Q4 2025.
• Announce topline data from the ARTEMIS trial in Q1 2027.
• Initiate a second Phase 3 registrational trial for Ixo-vec (implied as ARTEMIS is the first of two).

Key Dates

Recommendation

The accelerated timelines for the pivotal Phase 3 ARTEMIS trial, including earlier completion of screening, full enrollment, and topline data readout, represent a substantial de-risking event for Adverum Biotechnologies. For a clinical-stage company, advancing a lead asset through late-stage trials ahead of schedule is a strong indicator of operational efficiency and potential clinical success. This positive development, coupled with the significant market potential of a 'One And Done' gene therapy for wet AMD and multiple expedited regulatory designations, makes the stock a 'strong buy' for investors seeking exposure to innovative biotechnology with clear catalysts.

Keywords

Gene therapy, wet AMD, Ixo-vec, ARTEMIS trial, clinical trial, ophthalmology, AAV.7m8, aflibercept, Adverum Biotechnologies, ADVM